26 research outputs found
Effects of increased salinity on the diatom assemblage in Fonda Lake, Michigan
A salt storage facility has been located adjacent to Fonda Lake since 1953. In February 1981 a core was taken from the profundal sediments of the lake and analyzed to determine the effects of salt perturbation on the diatom community over a 32-year period. Diatom assemblages from different levels were compared using multivariate techniques including cluster analysis and principal component analysis. Shifts in diatom composition related to salinification were revealed most clearly by subdominant taxa. Five distinct groups of diatom taxa were found to correspond with 5 depth intervals. The diatom component of the lake up to 1960 included two groups of taxa which were alkaliphilous and chloride indifferent. A reduction in species diversity beginning in 1960 may indicate a salt effect. By 1968, when diversity reached a minimum, a variety of halophilic taxa (including Diatoma tenue, Navicula gregaria and Synedra fasciculata ) attained their highest relative abundances. At the top of the core, diversity increased slightly and some halophilic taxa decreased in relative abundance, which suggests a possible decrease in salt loading to the lake.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/42866/1/10750_2004_Article_BF00011577.pd
There is no age limit for methadone: a retrospective cohort study
BACKGROUND: Data from the US indicates that methadone-maintained populations are aging, with an increase of patients aged 50 or older. Data from European methadone populations is sparse. This retrospective cohort study sought to evaluate the age trends and related developments in the methadone population of Basel-City, Switzerland. METHODS: The study included methadone patients between April 1, 1995 and March 31, 2003. Anonymized data was taken from the methadone register of Basel-City. For analysis of age distributions, patient samples were split into four age categories from '20-29 years' to '50 years and over'. Cross-sectional comparisons were performed using patient samples of 1996 and 2003. RESULTS: Analysis showed a significant increase in older patients between 1996 and 2003 (p < 0.001). During that period, the percentage of patients aged 50 and over rose almost tenfold, while the proportion of patients aged under 30 dropped significantly from 52.8% to 12.3%. The average methadone dose (p < 0.001) and the 1-year retention rate (p < 0.001) also increased significantly. CONCLUSIONS: Findings point to clear trends in aging of methadone patients in Basel-City which are comparable, although less pronounced, to developments among US methadone populations. Many unanswered questions on medical, psychosocial and health economic consequences remain as the needs of older patients have not yet been evaluated extensively. However, older methadone patients, just as any other patients, should be accorded treatment appropriate to their medical condition and needs. Particular attention should be paid to adequate solutions for persons in need of care
Long-term effects of medical management on growth and weight in individuals with urea cycle disorders
Low protein diet and sodium or glycerol phenylbutyrate, two pillars of recommended long-term therapy of individuals with urea cycle disorders (UCDs), involve the risk of iatrogenic growth failure. Limited evidence-based studies hamper our knowledge on the long-term effects of the proposed medical management in individuals with UCDs. We studied the impact of medical management on growth and weight development in 307 individuals longitudinally followed by the Urea Cycle Disorders Consortium (UCDC) and the European registry and network for Intoxication type Metabolic Diseases (E-IMD). Intrauterine growth of all investigated UCDs and postnatal linear growth of asymptomatic individuals remained unaffected. Symptomatic individuals were at risk of progressive growth retardation independent from the underlying disease and the degree of natural protein restriction. Growth impairment was determined by disease severity and associated with reduced or borderline plasma branched-chain amino acid (BCAA) concentrations. Liver transplantation appeared to have a beneficial effect on growth. Weight development remained unaffected both in asymptomatic and symptomatic individuals. Progressive growth impairment depends on disease severity and plasma BCAA concentrations, but cannot be predicted by the amount of natural protein intake alone. Future clinical trials are necessary to evaluate whether supplementation with BCAAs might improve growth in UCDs
First Finding of the Amphipod \u3ci\u3eEchinogammarus ischnus\u3c/i\u3e and the Mussel \u3ci\u3eDreissena bugensis\u3c/i\u3e in Lake Michigan
The first finding of the amphipod Echinogammarus ischnus and the mussel Dreissena bugensis in Lake Michigan is documented. These two species are widespread and abundant in the lower lakes, but had not yet been reported from Lake Michigan. E. ischnus is generally considered a warmwater form that is typically associated with hard substrates and Dreissena clusters in the nearshore zone. Along the eastern shoreline of Lake Michigan, this species was present at rocky, breakwall habitats along the entire north-south axis of the lake. Although not abundant, this species was also found at soft-bottomed sites as deep as 94 m in the southern basin. The finding of this species in deep offshore waters apparently extends the known habitat range for this species in the Great Lakes, but it is found in deep water areas within its native range (Caspian Sea). D. bugensis was not abundant, but was present in both the southern and northern portions of the lake. Individuals of up to 36 mm in length were collected, indicating that it had probably been present in the lake for 2 or more years. Also presented are depth-defined densities of D. polymorpha at 37 sites in the Straits of Mackinac in 1997, and densities at up to 55 sites in the southern basin in 1992/93 and 1998/99. Mean densities decreased with increased water depth in both regions. Maximum mean density in the Straits in 1997 was 13,700/m2 (⤠10 m), and maximum density in the southern basin in 1999 was 2,100/m2 (⤠30 m). Mean densities at the ⤠30-m interval in the southern basin remained relatively unchanged between 1993 and 1999, but increased from 25/m2 to 1,100/m2 at the 31 to 50 m interval over the same time period. D. polymorpha was rare at sites \u3e 50 m. The presence of E. ischnus and the expected population expansion of D. bugensis will likely contribute to further foodweb changes in the lake
Cross-sectional multicenter study of patients with urea cycle disorders in the United States
Soccer as un-American activity: a thematic analysis of online US media and flopping in the worldâs game
Key Factors in Frame Building: How Strategic Political Actors Shape News Media Coverage
In this article, the author focuses on the relationship between political actors and the mass media. The author uses media frames as dependent variables and investigates the factors that influence the presence and frequency of frames applied by journalists (the frames in ânews mediaâ). This has come to be known as frame building. The author argues that there are at least three important factors in frame building: power, the salience of the frames in the media input, and the multiplication effect of the minister. Using data from content analyses of campaign material and news media and from interviews with political actors, the author finds support that for frame presence, power is important. For frame frequency, the salience of the frames in the media input and the minister are crucial
Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium
The Urea Cycle Disorders Consortium (UCDC) was created as part of a larger network established by the National Institutes of Health to study rare diseases. This paper reviews the UCDC's accomplishments over the first 6years, including how the Consortium was developed and organized, clinical research studies initiated, and the importance of creating partnerships with patient advocacy groups, philanthropic foundations and biotech and pharmaceutical companies